GT Healthcare Capital Partners

MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.

MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.

Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the development of surgical anastomotic technology aimed at treating obesity and type 2 diabetes. Founded in 2012, the company focuses on creating innovative solutions that facilitate less invasive surgical procedures, thereby expanding the range of available medical interventions. G.I. Windows is dedicated to improving healthcare outcomes by balancing the needs of patients with the overall efficiency of the healthcare system. Through its groundbreaking technology, the company aims to establish a new category in healthcare that not only enhances procedural effectiveness but also reduces costs associated with surgical treatments.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Oxford VR Limited, founded in 2016 and based in Oxford, United Kingdom, specializes in developing automated cognitive treatments for various clinical conditions, including fear of heights, psychosis, and social anxiety. Originating from research at Oxford University by Professor Daniel Freeman, the company harnesses immersive virtual reality technology to deliver therapy through a virtual coach. This innovative approach aims to significantly increase access to mental health treatments, making them faster, more effective, and lower in cost compared to traditional methods. Oxford VR focuses on creating clinically validated and user-centered therapies that not only benefit patients but also positively impact the healthcare system and the broader economy.

ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® radiosurgery platform. ZAP-X incorporates a unique self-shielded design that typically eliminates the need for traditional radiation vaults, and thus enables simple point-of-care delivery in locations previously unfeasible or cost-prohibitive, including physician offices, ambulatory surgery centers, and satellite facilities.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the development of surgical anastomotic technology aimed at treating obesity and type 2 diabetes. Founded in 2012, the company focuses on creating innovative solutions that facilitate less invasive surgical procedures, thereby expanding the range of available medical interventions. G.I. Windows is dedicated to improving healthcare outcomes by balancing the needs of patients with the overall efficiency of the healthcare system. Through its groundbreaking technology, the company aims to establish a new category in healthcare that not only enhances procedural effectiveness but also reduces costs associated with surgical treatments.

Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Oxford VR Limited, founded in 2016 and based in Oxford, United Kingdom, specializes in developing automated cognitive treatments for various clinical conditions, including fear of heights, psychosis, and social anxiety. Originating from research at Oxford University by Professor Daniel Freeman, the company harnesses immersive virtual reality technology to deliver therapy through a virtual coach. This innovative approach aims to significantly increase access to mental health treatments, making them faster, more effective, and lower in cost compared to traditional methods. Oxford VR focuses on creating clinically validated and user-centered therapies that not only benefit patients but also positively impact the healthcare system and the broader economy.

Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.

Potrero Medical, Inc. is a healthcare technology company focused on developing advanced monitoring devices that detect subtle changes in physiological parameters to enhance patient care in critical settings. Its innovative products provide early warnings for conditions such as sepsis and systemic inflammatory response syndrome, while also optimizing treatment by monitoring fluid levels during resuscitation. The company's devices measure various metrics, including intra-abdominal pressure, core body temperature, heart rate, respiratory rate, relative cardiac output, and urine output. Founded in 2011 and headquartered in Hayward, California, Potrero Medical aims to leverage smart sensors and artificial intelligence to create a predictive health platform that assists medical teams in anticipating adverse outcomes in critical care.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. The company leverages artificial intelligence to create diagnostic tools that significantly improve the accuracy of echocardiography, with reported enhancements exceeding 90%. Ultromics' technology focuses on analyzing complex data from electrocardiograms, enabling healthcare providers to make informed decisions in diagnosing coronary artery disease. By providing innovative solutions for cardiologists, Ultromics aims to transform cardiovascular diagnostics and improve patient outcomes.

RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.

Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.

Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.